Anzeige
Erschienen in:
22.02.2018 | Review articles
Efficacy of aliskiren supplementation for heart failure
A meta-analysis of randomized controlled trials
Erschienen in: Herz | Ausgabe 5/2019
Einloggen, um Zugang zu erhaltenAbstract
Background
Aliskiren might be beneficial for heart failure. However, the results of various studies are controversial. We conducted a systematic review and meta-analysis to explore the efficacy of aliskiren supplementation for heart failure.
Methods
PubMed, Embase, Web of Science, EBSCO, and the Cochrane Library databases were systematically searched. Randomized controlled trials (RCTs) assessing the efficacy of aliskiren for heart failure were included. Two investigators independently searched for articles, extracted data, and assessed the quality of included studies. The meta-analysis was performed using the random-effect model.
Results
Five RCTs comprising 1973 patients were included in the meta-analysis. Compared with control interventions in heart failure, aliskiren supplementation was found to significantly reduce NT-proBNP levels (standardized mean difference [SMD] = −0.12; 95% CI = −0.21 to −0.03 pg/ml; p = 0.008) and plasma renin activity (SMD = −0.66; 95% CI = −0.89 to −0.44 ng/ml.h; p < 0.00001) while increasing plasma renin concentration (SMD = 0.52; 95% CI = 0.30–0.75 ng/l; p < 0.00001); however, it demonstrated no significant influence on BNP levels (SMD = −0.08; 95% CI = −0.31–0.15 pg/ml; p = 0.49), mortality (RR = 0.97; 95% CI = 0.79–1.20; p = 0.79), aldosterone levels (SMD = −0.09; 95% CI = −0.32–0.14 pmol/l; p = 0.44), adverse events (RR = 3.03; 95% CI = 0.18–49.51; p = 0.44), and serious adverse events (RR = 1.34; 95% CI = 0.54–3.33; p = 0.53).
Conclusion
Aliskiren supplementation was found to significantly decrease NT-proBNP levels and plasma renin activity and to improve plasma renin concentration in the setting of heart failure.